Ruxolitinib for the Treatment of Prurigo Nodularis

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses the use of ruxolitinib, a Janus kinase (JAK1/JAK2) inhibitor, or its pharmaceutically acceptable salts (notably ruxolitinib phosphate), for the treatment of prurigo nodularis—a chronic skin condition characterized by intensely itchy nodules. The invention specifically covers topical formulations (such as creams) containing specific concentrations of ruxolitinib, methods of administration (e.g., once or twice daily), and demonstrates efficacy through clinical improvements in itch severity and skin lesion scores. The patent includes details on cream composition and supportive data on ruxolitinib’s ability to inhibit inflammatory cytokines related to prurigo nodularis.

Use CasesContent extracted from patent full text and abstract with AI.

• Topical treatment for patients diagnosed with prurigo nodularis to reduce itching and skin lesions.
• Adjunct therapy alongside other treatments (e.g., antihistamines, corticosteroids, immunomodulators) for recalcitrant or widespread prurigo nodularis.
• Potential use in dermatology clinics or for at-home patient use via prescription cream formulations.
• Therapeutic intervention for patient populations more susceptible to prurigo nodularis, including those with darker skin or comorbid inflammatory disorders.
• Integration into combination therapy regimens for chronic pruritic skin diseases with similar inflammatory profiles.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new, targeted therapy for prurigo nodularis addressing an unmet medical need where current treatments are often inadequate or have toxicity concerns.
• Reduces inflammation and itch via selective inhibition of JAK1/JAK2 pathways, targeting key cytokines involved in disease pathogenesis (e.g., IL-31, IL-17, IL-22).
• Topical administration allows for direct action at the skin site with potentially fewer systemic side effects compared to oral or systemic immunosuppressants.
• Improves patient quality of life—alleviating symptoms such as severe itching, sleep disturbance, and social impairment.
• Formulation is compatible with standard pharmaceutical excipients, stable over time, and practical for large-scale production and clinical use.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

This disclosure relates to ruxolitinib, or a pharmaceutically acceptable salt thereof, and its use in treating prurigo nodularis.